Bastard, Paul;Orlova, Elizaveta;Sozaeva, Leila;Lévy, Romain;James, Alyssa;Schmitt, Monica M.;Ochoa, Sebastian;Kareva, Maria;Rodina, Yulia;Gervais, Adrian;Le Voyer, Tom;Rosain, Jérémie;Philippot, Quentin;Neehus, Anna-Lena;Shaw, Elana;Migaud, Mélanie;Bizien, Lucy;Ekwall, Olov;Berg, Stefan;Beccuti, Guglielmo;Ghizzoni, Lucia;Thiriez, Gérard;Pavot, Arthur;Goujard, Cécile;Frémond, Marie-Louise;Carter, Edwin;Rothenbuhler, Anya;Linglart, Agnès;Mignot, Brigite;Comte, Aurélie;Cheikh, Nathalie;Hermine, Olivier;Breivik, Lars;Husebye, Eystein S.;Humbert, Sébastien;Rohrlich, Pierre;Coaquette, Alain;Vuoto, Fanny;Faure, Karine;Mahlaoui, Nizar;Kotnik, Primož;Battelino, Tadej;Trebušak Podkrajšek, Katarina;Kisand, Kai;Ferré, Elise M.N.;DiMaggio, Thomas;Rosen, Lindsey B.;Burbelo, Peter D.;McIntyre, Martin;Kann, Nelli Y.;Shcherbina, Anna;Pavlova, Maria;Kolodkina, Anna;Holland, Steven M.;Zhang, Shen-Ying;Crow, Yanick J.;Notarangelo, Luigi D.;Su, Helen C.;Abel, Laurent;Anderson, Mark S.;Jouanguy, Emmanuelle;Neven, Bénédicte;Puel, Anne;Casanova, Jean-Laurent;Lionakis, Michail S.
doi: 10.1084/jem.20210554pmid: 33890986
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.